 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...5859606162636465666768...858859» |
- Tavneos (avacopan) / Amgen
DESIGN OF AVACOSTAR: A REAL-WORLD STUDY OF AVACOPAN IN ANCA-ASSOCIATED VASCULITIS (AAV) () - May 29, 2024 - Abstract #EULAR2024EULAR_4270;
P
Avacopan was approved for the treatment of adult patients with severe active GPA and MPA in combination with rituximab or cyclophosphamide by the European Commission in January 2022... The AVACOSTAR study will be the largest real world evidence study conducted to date that evaluates long-term safety of novel therapeutics in GPA/MPA and is expected to yield important insights on the use of avacopan in GPA/MPA in a real-world setting, including continuation beyond 12 months.
- Tavneos (avacopan) / Amgen
AVACOPAN IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS: MULTICENTER PROSPECTIVE REAL-LIFE STUDY ON EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE () - May 29, 2024 - Abstract #EULAR2024EULAR_4267;
The AVACOSTAR study will be the largest real world evidence study conducted to date that evaluates long-term safety of novel therapeutics in GPA/MPA and is expected to yield important insights on the use of avacopan in GPA/MPA in a real-world setting, including continuation beyond 12 months. The addition of avacopan to AAV induction therapy allows for a significant reduction in CS in the early weeks of treatment, with a good safety profile and positively impacting the perception of patients' quality of life.
- Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB () - May 29, 2024 - Abstract #EULAR2024EULAR_4266;
The observational study suggests that combination therapy with RTX/CYC together with avacopan appears to be well promising in the selected AAV patient population. However, controlled prospective studies investigating treatment efficacy of the combination of RTX/CYC as well as avacopan have to be considered to confirm the results.
- REAL WORLD DATA FROM A SINGLE CENTER: SURVIVAL RATES OF TNFi AS FIRST AND SECOND LINE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4227;
TNFi display good overall survival rates as first line treatment among PsA with inadequate response to cDMARDs. Female gender and peripheral involvement are independent risk factors for early secondary inefficacy to first TNFi.
- Tremfya (guselkumab) / J&J
COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4174;
Adults with PsA newly initiated on guselkumab or the first observed SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or SC golimumab) between 7/14/2020 and 3/31/2022 were selected from the IQVIA TM Health Plan Claims Data. This real-world study assessing treatment persistence in PsA using administrative claims data demonstrated that guselkumab was associated with significantly longer on-label persistence through 12 months versus SC TNFi.
- INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_4000;
It appears that the risk of relapse of inflammation in patients receiving bDMARDs is high. Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
COMPARATIVE EFFECTIVENESS OF OSTEOPOROSIS MEDICATIONS ON DISEASE ACTIVITY IN RHEUMATIC MUSCULOSKELETAL DISORDERS () - May 29, 2024 - Abstract #EULAR2024EULAR_3970;
Fracture risk might mediate the effect of osteoporosis medications and disease activity control. Larger pragmatic trials are warranted.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
TIME AND TREATMENT AS KEY FACTORS IN THE DEVELOPMENT OF UVEITIS IN JUVENILE IDIOPATHIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3936;
More than half of the patients developed uveitis while not receiving systemic treatment. We observed that those receiving methotrexate as monotherapy had a higher frequency of uveitis compared to other treatments.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
LONG-TERM EFFICACY OF ETANERCEPT AND ADALIMUMAB IN A COHORT OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3927;
Long-term treatment with ETN and ADA has been shown to be effective and safe for patients with JIA, as evidenced by the high retention rate recorded in our cohort. Most patients maintain current therapy for years to preserve remission status.
- Enbrel (etanercept) / Pfizer, Amgen
INCREASED INCIDENCE OF ADVERSE EVENTS AND EVENTS OF SPECIAL INTEREST WITH TREATMENT INTENSIFICATION IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3921;
Risk of AEs increased, and AE severity worsened with treatment intensification, with bDMARDs associated with a higher prevalence of AE, SAE and ESI when compared to treatment with csDMARDS or NSAIDs. The most frequent ESIs were infections.
- Enbrel (etanercept) / Pfizer, Amgen
LATE-ONSET JIA-RELATED UVEITIS: A SINGLE-CENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3861;
However, a non-negligible portion of patients with risk factors for uveitis appear even after many years of disease; therefore, long-term follow-up would appear to be the most prudent approach in this subgroup of patients. Table 1.
- DISEASE FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING COVID-19 BREAKTHROUGH INFECTION: RESULT FROM COVAD E-SURVEY STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3841;
Table 1. Younger age (odds ratio (OR): 0.98, 95% CI: 0.96
- WHAT IS THE TRUTH? - COMPARISON OF REACTIONS AND ADVERSE EVENTS BETWEEN JAK INHIBITORS AND ANTI-TNFS - REAL LIFE EXPERIENCE () - May 29, 2024 - Abstract #EULAR2024EULAR_3757;
No major cardiovascular events or thrombotic events were found in a great population of patients using JAKs inhibitors in recent two years. Larger studies are required in the Latin American population to confirm these results.
- VIRAL INFECTIONS AMONG PATIENTS RECEIVING BIOLOGICS FOR RHEUMATIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_3673;
Biological therapies, especially TNF alpha inhibitors, may lead to an increased risk of viral infections. These infections were reported in 6% of our patients.
- Enbrel (etanercept) / Pfizer, Amgen
SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT () - May 29, 2024 - Abstract #EULAR2024EULAR_3622;
70% of the BRAGGSS population self-reported adherence to their medication. Factors associated with non-adherence such as TJC and belief in medication necessity may allow targeting of interventions to optimise adherence in these groups.
- PREDICTIVE FACTORS FOR GOOD RESPONSE TO RHEUMATOID ARTHRITIS WITH BIOLOGICAL TARGETED THERAPIES () - May 29, 2024 - Abstract #EULAR2024EULAR_3594;
Factors associated with non-adherence such as TJC and belief in medication necessity may allow targeting of interventions to optimise adherence in these groups. All patients had active RA before biotherapy with a DAS28 score average initial of 5.42
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING TNF INHIBITORS IN REAL LIFE IN FRANCE IN 2016-2022 ARE DIFFERENT FROM PATIENTS INCLUDED IN SIMILAR COHORTS AND IN CLINICAL TRIALS. DATA FROM THE ART-SFR REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3583;
P=N/A
Given the design of the registry, their characteristics can be considered representative of those of patients initiating TNFi for RA in France. Most patients in the registry were treated in accordance with recommendations.
- Humira (adalimumab) / AbbVie
NON-MEDICAL SWITCH OF BIOLOGIC DRUGS IN PATIENTS WITH RHEUMATIC DISEASE () - May 29, 2024 - Abstract #EULAR2024EULAR_3572;
Patients with SpA were the most affected. Golimumab has the preferred application device.
- Enbrel (etanercept) / Pfizer, Amgen
NEUTROPHIL-TO-LYMPHOCYTE RATIO, LEUKOCYTIC FORMULA REVERSAL AND PREVALENCE OF LARGE GRANULAR T LYMPHOCYTE LEUKEMIA IN AN ITALIAN MONOCENTRIC RHEUMATOID ARTHRITIS COHORT () - May 29, 2024 - Abstract #EULAR2024EULAR_3568;
Our results confirm that the NLR may be an additional marker of disease activity and worse response to b/tsDMARD treatment (MDR-RA). The use of TNFi is associated with higher rates of N/L reversal in patients in remission or low disease activity, whereas it does not seem to mask increases in NLR in moderate or high activity conditions.
- methotrexate / Generic mfg.
EARLY RESPONDERS TO REMISSION-INDUCTION TREATMENT WITH METHOTREXATE AND BRIDGING GLUCOCORTICOIDS REPORT LOWER RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) OVER 2 YEARS: SECONDARY ANALYSIS OF THE CARERA2020 TRIAL () - May 29, 2024 - Abstract #EULAR2024EULAR_3482;
Almost one-in-two patients in this early RA trial experienced persisting disease impact despite intensive DMARD treatment in a protocolised treat-to-target setting. However, lower long-term disease impact was seen with early achievement of treatment targets, confirming similar findings from the preceding CareRA trial and other early RA cohorts.
- Humira (adalimumab) / AbbVie
DRUG SURVIVAL ON FIRST BIOLOGIC THERAPY AMONG ELDERLY-ONSET RHEUMATOID ARTHRITIS PATEINTS COMPARED TO YOUNG-ONSET PATIENTS: A POPULATION-BASED COHORT STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3479;
Figure 1. Study population.
- DRUG SURVIVAL AND PREDICTOR FACTORS FOR DISCONTINUATION OF FIRST-LINE BIOLOGIC THERAPY: DATA FROM A REAL-WORLD SINGLE CENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3478;
Longer disease duration and higher disease activity at baseline, as well as more comorbidities and extra-articular manifestations were associated with early discontinuation of the first bDMARD therapy. RF and ACPA negativity predicted better drug survival.
- Remicade (infliximab) / J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen
DO RHEUMATOID ARTHRITIS PATIENTS IN REMISSION NEED SYMPTOMATIC TREATMENTS? () - May 29, 2024 - Abstract #EULAR2024EULAR_3474;
Despite clinical remission, our patients did not stop using symptomatic treatments. This may be suggestive of persistent pain due to several underlying mechanisms.
- Humira (adalimumab) / AbbVie
CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3457;
MOA switchers showed greater prevalence of arterial hypertension as well as higher titles of ESR and higher disease activity at baseline according to DAS28-ESR three variables. These findings may influence therapeutic decisions, but further investigation is needed.
- Olumiant (baricitinib) / Eli Lilly, Enbrel (etanercept) / Pfizer, Amgen, Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
CONTRIBUTION OF SECRETED SYNOVIAL TISSUE PROTEINS TO SERUM INFLAMMATORY PROFILES, CLINICAL FEATURES, AND THERAPEUTIC RESPONSES IN RHEUMATOID ARTHRITIS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_3453;
We have identified a ten-protein signature, secreted by the synovial tissue, that seems to contribute to the circulating inflammatory profile of RA patients. 2.
- Enbrel (etanercept) / Pfizer, Amgen
COMPARISON OF THE EFFICACY OF ETANERCEPT VERSUS MONOCLONAL TNF INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE CZECH NATIONAL ATTRA REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3452;
Results vary slightly over time depending on the method of assessment used. Future real-world observational studies should aim to identify specific factors to predict response to treatment and/or stratify the relative efficacy of bDMARDs by specific line of treatment.
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
CLINICLAL EFFICACY OF SEQUENTIAL TREATMENT AFTER ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH PRIMARY OSTEOPOROSIS FOR 24 MONTHS () - May 29, 2024 - Abstract #EULAR2024EULAR_3446;
Objectives: To evaluate the clinical efficacy of ROMO for 12 months and denosumab (DMB) for 12 months in patients with RA-OP comparison with primary osteoporosis (P-OP) for 24 months. Clinical efficacy of treatment with ROMO for 12months and DMB for 12months was extremely effective for RA-OP as well as for P-OP and has the high potential to be an important option in the treatment of RA-OP.
- dazodalibep (HZN-4920) / Amgen
CD40L BLOCKADE WITH DAZODALIBEP SIGNIFICANTLY IMPROVES DISEASE ACTIVITY, SWOLLEN AND TENDER JOINT COUNTS, WHILE REDUCING MULTIPLE T- AND B-CELL BIOMARKERS IN THE MIDORA PHASE 2 STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3431;
P2
Additionally, DAZ reduced biomarkers of T- and B-cell costimulatory blockade, and inhibition of GC formation activity, and autoantibody production. Together, these data demonstrate the biological impact of CD40-CD40L pathway blockade on selected blood biomarkers in RA.
- EFFECTIVENESS OF JANUS KINASE INHIBITORS IN REFRACTORY TAKAYASU ARTERITIS. CASE REPORTS AND LITERATURE REVIEW () - May 29, 2024 - Abstract #EULAR2024EULAR_3356;
In the literature review we found 55 patients (44 women and 11 men) with TA treated with JAKi: TOFA (n=52), BARI (n=2), and ruxolitinib (n=1). JAKi appear to be a relatively effective and safe treatment, even in TA refractory to cDMARDs and/or bDMARDs.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
NO PREDICTIVE EFFECT OF OBESITY ON CLINICAL RESPONSE IN PATIENTS WITH RA AND SpA AFTER 3 YEARS OF BIOLOGIC DRUGS: A MULTICENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3171;
Thus no personalized treatment strategy should be considered for obese patients. Specific studies using DEXA examining the direct impact of obesity, and, ideally, of fat mass, on the therapeutic response of recently licensed bDMARDs and tsDMARDs are required.
- Humira (adalimumab) / AbbVie
SWITCHING FROM TNF INHIBITORS TO TOFACITINIB AMONG PATIENTS WITH STABLE DISEASE DUE TO COST IMPLICATIONS: DIFFERENTIAL LOSS OF RESPONSE IN MAJORITY OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES () - May 29, 2024 - Abstract #EULAR2024EULAR_3041;
There is paucity of data as regards switching therapy among patients with adequate disease control. Our prospective study shows that majority of patients have relapse of their inflammatory arthritis, and it was significantly higher among patients with AS, with 70% of patients having relapse of their disease.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
EFFECTS OF ONE-YEAR ANTI-TNF-? THERAPY ON NATURAL AUTOANTIBODIES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3007;
Biologic therapy also increased anti-CS and anti-TOPO-F4 levels. The production of nAAbs was variably associated with, among other parameters, CRP, disease activity and vascular pathophysiology suggesting that nAAbs might form a link between arthritis and atherosclerosis.
- Krystexxa (pegloticase) / Amgen
PATIENT-REPORTED QUALITY OF LIFE IN UNCONTROLLED GOUT AND CHANGES WITH INTENSIVE URATE-LOWERING: COMPARISON OF TOPHACEOUS AND NON-TOPHACEOUS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2979;
However, full QOL improvements took longer in patients with tophi, presumably due to their higher urate burden at baseline. Prior publications have established that 52 weeks of pegloticase treatment results in near-total depletion of deposited urate.[6,7] Therefore, the current findings clinically support the known association between tophi and quality of life impact,[1,2] also suggesting that tophaceous gout patients in particular may benefit from a longer pegloticase treatment course.
- Krystexxa (pegloticase) / Amgen
INFLUENCE OF ACUTE GOUT FLARE AND SERUM URATE LOWERING ON BIOMARKERS OF SYSTEMIC INFLAMMATION () - May 29, 2024 - Abstract #EULAR2024EULAR_2974;
With prolonged SU-lowering, subsequent deposited urate depletion,[11,12] and flare cessation, transient increases in hsCRP and IL-6 were no longer observed and mean biomarker levels remained at/slightly below pre-treatment values. Of note, biomarker levels were highly variable between patients and further study is needed to confirm a relationship between gout flares and inflammatory biomarker levels.
- Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis
UVEITIS IN AXIAL SPONDYLOARTHRITIS: STUDY OF 309 PATIENTS IN A SINGLE UNIVERSITY CENTER () - May 29, 2024 - Abstract #EULAR2024EULAR_2951;
Most patients with uveitis had positive HLA-B27 and severe sacroilitis in x-ray was more frequent. The most frequent pattern of uveitis observed in axSpA was acute, anterior and unilateral.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
THE INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS WITH SPONDYLOARTHRITIS UNDER BIOTHERAPY IN THE MOROCCAN REGISTRY OF BIOTHERAPY: 3-YEAR FOLLOW-UP () - May 29, 2024 - Abstract #EULAR2024EULAR_2941;
The incidence of fungal infections in patients with spondyloarthritis is low, and remains similar to data in the literature. It seems to be related to disease activity and type of biologics.
- Enbrel (etanercept) / Pfizer, Amgen
PROMINENT OSTEOPROLIFERATIVE CHANGES OF THE AXIAL SPINE IN THE PRESENCE OF CHRONIC KIDNEY DISEASE ACCOMPANYING SPONDYLOARTHRITIS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2917;
On the other hand, one-fifth of CKD patients without SpA had syndesmophyte-like osteoproliferation. There is a significant increase in the mSASSS score in SpA patients with CKD.
- PATTERNS OF bDMARDs PRESCRIPTION IN SPONDYLOARTHRITIS AFTER FIRST TNFi FAILURE () - May 29, 2024 - Abstract #EULAR2024EULAR_2902;
Since 2017, novel targets have emerged, and IL-17i have showed efficacy in controlling disease activity. In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
HOW ARE PATIENT REPORTED OUTCOME MEASUREMENTS USED IN AXIAL SPONDYLOARTHRITIS? A QUALITATIVE STUDY WITH HEALTH CARE PROFESSIONALS AND PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2884;
People with axSpA would appreciate adequate information for their completion. Resistance to complete the questionnaires could be tackled with best practice examples on how to do it efficiently.
- FACTORS ASSOCIATED WITH CAUSE-SPECIFIC DISCONTINUATION OF LONG-TERM ANTI-TUMOR NECROSIS FACTOR AGENT USE IN PATIENTS WITH ANKYLOSING SPONDYLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_2880;
AS patients on their first anti-TNF treatment for at least two years demonstrated a favorable long-term treatment retention rate, with a 24.0% discontinuation rate over a 10.6-year overall survival period. The predictors for discontinuation varied by causes, underscoring the complexity of treatment response and the importance of personalized approaches to treatment management.
- Enbrel (etanercept) / Pfizer, Amgen
EFFECTS OF ETANERCEPT AND/OR CELECOXIB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK RESULTS OF RANDOMIZED CONTROL TRIAL () - May 29, 2024 - Abstract #EULAR2024EULAR_2871;
The predictors for discontinuation varied by causes, underscoring the complexity of treatment response and the importance of personalized approaches to treatment management. Combined treatment of etanercept and celecoxib provides clinically meaningful improvements in health-related QoL in patients with active AS.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
DO MORE THERAPEUTIC OPTIONS LEAD TO A DECLINE IN THE RETENTION RATE OF BIOLOGICALS? A REAL-WORLD STUDY IN PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2867;
Although the 1-year retention rates in both PsA and SpA groups who received their first b/tsDMARD treatment between 2012-2016 were numerically slightly higher than in the groups who received their first dose of b/tsDMARD between 2017-2022, no statistically significant difference was found. Specific patient profiles for failure on the first bDMARD/tsDMARD therapy could not be identified.
- Prolia (denosumab) / Amgen
IMPACT OF GLUCOCORTICOIDS ON THE THERAPEUTIC EFFICACY OF DENOSUMAB IN OSTEOPOROSIS OF RHEUMATOID ARTHRITIS PATIENTS (Poster Tour 3) - May 29, 2024 - Abstract #EULAR2024EULAR_2841;
Specific patient profiles for failure on the first bDMARD/tsDMARD therapy could not be identified. Our results suggest that GIOP dose of GC attenuates the therapeutic efficacy of denosumab in increasing BMD in RA, particularly in the subgroup of patients negative for anti-CCP antibodies.
- | Neulasta (pegfilgrastim) / Roche
Preclinical, Journal: Effects of combined ciprofloxacin and Neulasta therapy on intestinal pathology and gut microbiota after high-dose irradiation in mice. (Pubmed Central) - May 29, 2024
This study provides a framework for the identification of microbial elements that may influence radiosensitivity, biodosimetry and the efficacy of potential therapeutics. Moreover, increased survival from H-ARS using these therapeutics may affect the symptoms and appearance of what may have been subclinical GI-ARS.
- || Stivarga (regorafenib) / Bayer
Retrospective data, Review, Journal, Monotherapy, Metastases: Regorafenib plus programmed death?1 inhibitors vs. regorafenib monotherapy in second?line treatment for advanced hepatocellular carcinoma: A systematic review and meta?analysis. (Pubmed Central) - May 29, 2024
However, R-P treatment was associated with an increased incidence of adverse events, such as hypothyroidism, thrombocytopenia and rash, compared with that in regorafenib. In conclusion, R-P is superior to regorafenib monotherapy in terms of survival benefits and tumor response.
- | Rituxan (rituximab) / Roche
Trial completion, Trial completion date, Combination therapy: Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 29, 2024
P1/2, N=48, Completed, Sponsor: Case Comprehensive Cancer Center
In conclusion, R-P is superior to regorafenib monotherapy in terms of survival benefits and tumor response. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2023
- | Blincyto (blinatumomab) / Astellas, Amgen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 29, 2024
P2, N=20, Recruiting, Sponsor: Brian Jonas
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2023 Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Feb 2025
- || maridebart cafraglutide (AMG 133) / Amgen
Enrollment closed: A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - May 28, 2024
P1, N=20, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Feb 2025 Recruiting --> Active, not recruiting
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: MicroRNA Profile and Erenumab Treatment (clinicaltrials.gov) - May 28, 2024
P=N/A, N=40, Completed, Sponsor: University of L'Aquila
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | vadacabtagene leraleucel (JCAR015) / BMS
Trial completion date, Trial primary completion date: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2024
P1, N=17, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025